Gotaric (Febuxostat)

Gotaric is indicated for the long‑term management of conditions associated with elevated uric acid.

• Reduction of serum uric acid in patients with gout.
• Prevention of gout flares in individuals with chronic hyperuricemia.
• Adjunct therapy when allopurinol is not tolerated or ineffective.
• Management of uric acid levels in patients with renal impairment, when dosage adjustment is appropriate.
• Use in combination with lifestyle modifications to maintain target uric acid concentrations.

Like other uric acid‑lowering agents, Gotaric may cause a range of adverse effects, most of which are mild and reversible.

Common

• Headache, dizziness, or fatigue.
• Mild gastrointestinal symptoms such as nausea, abdominal pain, or diarrhea.
• Elevated liver enzymes detected in routine blood tests.
• Transient joint discomfort or swelling.

Serious

• Severe hypersensitivity reactions, including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Acute renal failure or worsening kidney function.
• Cardiovascular events such as myocardial infarction or stroke.
• Liver failure or hepatic necrosis.
• Blood dyscrasias, for example neutropenia or thrombocytopenia.

Before initiating Gotaric, healthcare providers should evaluate patient history and monitor specific clinical parameters to minimize risks.

• Assess renal and hepatic function; dose adjustments may be required in impairment.
• Review cardiovascular history, as the drug may be associated with ischemic events.
• Avoid use in patients with known hypersensitivity to febuxostat or other xanthine oxidase inhibitors.
• Monitor serum uric acid and liver enzymes regularly during therapy.
• Counsel patients on maintaining adequate hydration and adhering to dietary recommendations.
• Consider alternative therapy during pregnancy or breastfeeding due to limited safety data.

Gotaric can interact with several medicines, affecting its efficacy or safety profile; clinicians should review concomitant drugs carefully.

Avoid

• Concomitant use with azathioprine or mercaptopurine, which may increase toxicity.
• Co‑administration with strong CYP3A4 inducers (e.g., rifampin) that can reduce febuxostat exposure.

Use with caution

• Warfarin, as febuxostat may enhance anticoagulant effect; monitor INR.
• Simvastatin or other statins, due to potential increased risk of myopathy.
• NSAIDs, especially high‑dose ibuprofen, which may affect renal function when combined.